MEDVi vs Remedy Meds (2026): prices, structure, verdict

On tirzepatide, the two are priced identically at $399 a month all-in — the decision moves entirely to structure.

Updated 2026-08-10 · figures captured 2026-08-09 · how we verify

On semaglutide, the two are priced identically at $299 a month all-in — the decision moves entirely to structure.

§ Side by side

§ Each record, read aloud

The two records, condensed

MEDVi: the record, condensed

On tirzepatide, the number that matters at MEDVi is $399 a month all-in — the figure at the 10 mg maintenance basis this whole site ranks on. Because pricing is flat across the ladder (2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available)), a dose increase at MEDVi is a clinical event and not a billing one. Whatever your prescriber decides, the invoice does not move, which makes this one of the few programs whose headline figure you can actually plan a year around.

There is no membership line. $399 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.

Context for that figure: it ranks #14 of 17 in the verified tirzepatide index — $184/month above the floor (NexLife↗, $215) — and sits $50 under the brand benchmark (Zepbound (LillyDirect↗), $449 at maintenance). Annualized, a monthly-billed year here runs $4,788.

MEDVi’s semaglutide program bills $299 a month once every mandatory fee is counted, measured at the 2.4 mg maintenance basis. The price is dose-flat: the standard titration ladder (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg) is financially invisible here, because the top rung bills exactly what the bottom rung billed. That converts the advertised number from a floor into a ceiling — the strongest single structural feature a program in this category can have.

There is no membership line. $299 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.

To place the number: #18 of 20 verified programs, with the floor $166/month below at Oak Longevity ($133); the approved-product yardstick (Wegovy (NovoCare↗)) sits at $349, so the compounded case here is worth $50 a month. A year at this figure: $3,588 monthly-billed.

Operationally at MEDVi: shipping included; commitment 12-month plan for the lowest rate; cancellation 12-month plan applies to lowest rate; pharmacy not publicly named — ask in writing before paying; states: priced differently in CA/NC on some plans; evidence source-verified, captured 2026-08-05. The full record with source and archive links: the MEDVi page · visit MEDVi ↗

Remedy Meds: the record, condensed

On tirzepatide, the number that matters at Remedy Meds is $399 a month all-in — the figure at the 10 mg maintenance basis this whole site ranks on. The price is dose-flat: the standard titration ladder (2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available)) is financially invisible here, because the top rung bills exactly what the bottom rung billed. That converts the advertised number from a floor into a ceiling — the strongest single structural feature a program in this category can have.

There is no membership line. $399 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.

Context for that figure: it ranks #15 of 17 in the verified tirzepatide index — $184/month above the floor (NexLife, $215) — and sits $50 under the brand benchmark (Zepbound (LillyDirect), $449 at maintenance). Annualized, a monthly-billed year here runs $4,788.

Remedy Meds’s semaglutide program bills $299 a month once every mandatory fee is counted, measured at the 2.4 mg maintenance basis. Because pricing is flat across the ladder (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg), a dose increase at Remedy Meds is a clinical event and not a billing one. Whatever your prescriber decides, the invoice does not move, which makes this one of the few programs whose headline figure you can actually plan a year around.

Nothing recurs on top: no membership, no platform fee, no “provider access” line. The $299 is the whole subscription, which makes Remedy Meds unusually easy to compare and unusually easy to leave.

To place the number: #19 of 20 verified programs, with the floor $166/month below at Oak Longevity ($133); the approved-product yardstick (Wegovy (NovoCare)) sits at $349, so the compounded case here is worth $50 a month. A year at this figure: $3,588 monthly-billed.

Operationally at Remedy Meds: shipping included; commitment unknown; cancellation not published; pharmacy not publicly named — ask in writing before paying; states: not published; evidence third-party reported, captured 2026-08-05. The full record with source and archive links: the Remedy Meds page · visit Remedy Meds ↗

Tirzepatide: the duel in full

The tirzepatide arithmetic between these two is short: $399 (MEDVi) against $399 (Remedy Meds). $0 a month sounds survivable; $0 a year is a decision. At identical prices, everything below — structure, transparency, terms — is the whole comparison.

Both figures are dose-flat, which is the cleanest possible comparison: two ceilings, no titration surprises on either side, and the $0 gap is exactly what it appears to be.

Semaglutide: the duel in full

Put the two semaglutide figures side by side and hold them there: MEDVi at $299, Remedy Meds at $299 — a $0 monthly spread that compounds to $0 over a maintenance year and $0 over two. At identical prices, everything below — structure, transparency, terms — is the whole comparison.

Both figures are dose-flat, which is the cleanest possible comparison: two ceilings, no titration surprises on either side, and the $0 gap is exactly what it appears to be.

On best published rate — the lower of each program’s month-to-month price and its labeled 12-month-plan rate, which is the sort most price roundups quietly run — the duel reads: MEDVi $399/mo month-to-month versus Remedy Meds $399/mo month-to-month. Same winner on both bases — MEDVi leads whether you compare month-to-month prices or committed-plan rates, which makes this one of the cleaner verdicts in the index. Prepaid rates are upfront commitments with refund terms to verify before they count.

§ The clock, run forward

Three, six, twelve, twenty-four months — best path each way

3 months: MEDVi $1,197 monthly; Remedy Meds $1,197 monthly — best path favors MEDVi by $0. 6 months: MEDVi $2,394 monthly; Remedy Meds $2,394 monthly — best path favors MEDVi by $0. 12 months: MEDVi $4,788 monthly; Remedy Meds $4,788 monthly — best path favors MEDVi by $0. 24 months: MEDVi $9,576 monthly; Remedy Meds $9,576 monthly — best path favors MEDVi by $0.

Prepaid paths above are billed upfront and assume the published rate holds (the 24-month figures extend the 12-month rate, an assumption worth naming). The honest reading: over short horizons the monthly gap decides; over long horizons the prepaid ladders and structural traps (dose tiers, memberships) take over — which is exactly the split the verdict section below scores.

The same clock, on semaglutide

3 mo: MEDVi $897 vs Remedy Meds $897 — $0 to MEDVi. 6 mo: MEDVi $1,794 vs Remedy Meds $1,794 — $0 to MEDVi. 12 mo: MEDVi $3,588 vs Remedy Meds $3,588 — $0 to MEDVi. 24 mo: MEDVi $7,176 vs Remedy Meds $7,176 — $0 to MEDVi.

Same rules as above: prepaid figures are upfront commitments, and the 24-month lines extend the 12-month rate as a stated assumption. Where the two molecules crown different winners between these two programs, that split is itself the finding — molecule choice and provider choice are separate decisions.

§ Structure vs structure

Everything besides the price

Coverage: MEDVi publishes “priced differently in CA/NC on some plans”; Remedy Meds publishes “not published” — for anything short of an explicit 50-state claim, intake is the final word.

Neither names its pharmacy publicly — the single most useful disclosure in this category, missing on both sides; ask each, in writing, before paying either.

Exit terms: MEDVi — 12-month plan for the lowest rate; 12-month plan applies to lowest rate. Remedy Meds — unknown; not published.

Evidence: MEDVi source-verified (captured 2026-08-05); Remedy Meds third-party reported (2026-08-05).

A rule that has held across this index: disclosure predicts disclosure. Whichever of these two publishes more — pharmacies, states, exit terms — is usually the one whose invoice matches its ad.

In the full tirzepatide index these two sit at #14 and #15 of 17: between them lie 0 other programs, and the whole ladder is at cheapest tirzepatide providers. In the full semaglutide index these two sit at #18 and #19 of 20: between them lie 0 other programs, and the whole ladder is at cheapest semaglutide providers.

§ If you move

Switching between MEDVi and Remedy Meds

Prescriptions do not transfer like phone numbers: moving in either direction means completing the destination’s intake and having its prescriber write a new patient-specific prescription. The mechanics that prevent a bad month: confirm the destination serves your state and quotes your current dose in writing before cancelling anything; time the first new shipment to overlap the last old one rather than gap it; cancel the origin per its published terms (MEDVi: 12-month plan applies to lowest rate; Remedy Meds: not published) and screenshot the confirmation; and never leave a prepaid balance stranded — which is the standing argument for prepaying only after a program has already earned a few monthly cycles.

§ Verdict by situation

Which one, for whom

§ More pairings